Connect Biopharma Holdings Stock Today
| CNTB Stock | USD 0.92 0.05 5.15% |
PerformanceVery Weak
| Odds Of DistressLow
|
Connect Biopharma is trading at 0.92 as of the 16th of February 2025, a 5.15 percent decrease since the beginning of the trading day. The stock's open price was 0.97. Connect Biopharma has about a 24 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 17th of January 2025 and ending today, the 16th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of March 2021 | Category Healthcare | Classification Health Care |
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company was founded in 2012 and is headquartered in Taicang, China. The company has 55.25 M outstanding shares of which 31.34 K shares are currently shorted by private and institutional investors with about 1.53 trading days to cover. More on Connect Biopharma Holdings
Moving against Connect Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Connect Stock Highlights
| CEO Director | Barry PharmD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsConnect Biopharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Connect Biopharma's financial leverage. It provides some insight into what part of Connect Biopharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Connect Biopharma Holdings (CNTB) is traded on NASDAQ Exchange in USA. It is located in 12265 El Camino Real, San Diego, CA, United States, 92130 and employs 81 people. Connect Biopharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 50.97 M. Connect Biopharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 55.25 M outstanding shares of which 31.34 K shares are currently shorted by private and institutional investors with about 1.53 trading days to cover.
Connect Biopharma Holdings currently holds about 1.28 B in cash with (47.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Connect Biopharma Probability Of Bankruptcy
Ownership AllocationConnect Biopharma holds a total of 55.25 Million outstanding shares. Connect Biopharma Holdings retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Connect Ownership Details
Connect Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Keudell/morrison Wealth Management | 2024-12-31 | 0.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 0.0 | |
| Qube Research & Technologies | 2024-09-30 | 0.0 | |
| Bml Capital Management Llc | 2024-09-30 | 2.1 M | |
| Ubs O'connor Llc | 2024-09-30 | 510.7 K | |
| Renaissance Technologies Corp | 2024-09-30 | 175.5 K | |
| Rsm Us Wealth Management Llc | 2024-12-31 | 160.9 K | |
| Callan Capital, Llc | 2024-12-31 | 80 K | |
| Royal Bank Of Canada | 2024-09-30 | 30.6 K | |
| Geode Capital Management, Llc | 2024-09-30 | 28 K | |
| Commonwealth Equity Services Inc | 2024-09-30 | 20 K |
Connect Biopharma Historical Income Statement
Connect Stock Against Markets
Connect Biopharma Corporate Management
| Raul Collazo | VP Affairs | Profile | |
| Kimberly Manhard | Chief Officer | Profile | |
| Malinda Longphre | Head Operations | Profile | |
| Jeff JD | General Secretary | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Connect Biopharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.